Imcyse raises €35M in series B funding and additional grants
Imcyse - ImotopesTM autoimmune disease treatment
Type 1 diabetes not an increased risk for a COVID-19 hospital admission | UZ Leuven
Imcyse's €35M Series B to Fund Potential Type 1 Diabetes Cure
Imcyse - Rethinking T1D: Saving Beta Cells with Targeted Immunotherapy - YouTube
IMPACT Study – T1DUK
Imcyse SA -
Imcyse raises •35M in series B funding and additional grants
Imcyse - Technology Platform
Towards a first precision medicine Immunotherapy for the treatment of Type 1 Diabetes using Ariana's Artificial Intelligence - Ariana Pharma
Imcyse - About Us
Towards a first precision medicine Immunotherapy for the treatment of Type 1 Diabetes using Ariana's Artificial Intelligence - Ariana Pharma
Belgian company Imcyse to start human trials of type 1 diabetes vaccine - Diabetes
Imcyse's €35M Series B to Fund Potential Type 1 Diabetes Cure
Imcyse - Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
Imcyse closes €21.3m Series B as new partner Pfizer takes equity stake - Pharmaceutical Technology
Imcyse's Type 1 Diabetes Immunotherapy Shows Promise in Phase I
Imcyse - ImotopesTM autoimmune disease treatment
Imcyse - Rethinking T1D: Saving Beta Cells with Targeted Immunotherapy - YouTube
Colin Dayan - Media Centre | EASD
BERNAMA - Beware Of Risk Of Diabetes In Children Infected By COVID-19
Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure
